Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
Open access · greenAbstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Therapeutic targeting of post-translational modifications in ovarian cancer: mechanisms and clinical applications.Journal of ovarian research · 2025Review
- Poly (ADP-Ribose) Polymerase 1 and 2 in B-Cell Lymphoma: Pathogenic Roles and Therapeutic Implications.The American journal of pathology · 2025Review
- Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.Haematologica · 2024Article
- Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens.Journal of translational medicine · 2024Article
- Review
- SAMHD1 expression contributes to doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma patients.NAR cancer · 2024Article
- Targeting the DNA damage response in hematological malignancies.Frontiers in oncology · 2024Review
- A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.Cancer chemotherapy and pharmacology · 2022Article
- Article
- Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment.Experimental hematology & oncology · 2021Review
- Review
- Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort.Scientific reports · 2020Article
- PARP Inhibition in Cancer: An Update on Clinical Development.Targeted oncology · 2019Review
- LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.Cancer cell · 2019Article
- Restriction of AID activity and somatic hypermutation by PARP-1.Nucleic acids research · 2019Article
- Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies.Oxidative medicine and cellular longevity · 2018Review
- PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 5 institutions in 2 countries.
Jacob D SoumeraiDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York. soumeraj@mskcc.org.
Andrew D ZelenetzDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Craig H MoskowitzDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
M Lia PalombaDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Paul A HamlinDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Ariela NoyDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
David J StrausDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Alison J MoskowitzDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Anas YounesDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Matthew J MatasarDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Steven M HorwitzDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Carol S PortlockDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Jason A KonnerDepartment of Medicine, Center for Developmental Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York.
Mrinal M GounderDepartment of Medicine, Center for Developmental Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York.
David M HymanDepartment of Medicine, Center for Developmental Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York.
Martin H VossDepartment of Medicine, Center for Developmental Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York.
Matthew G FuryDepartment of Medicine, Center for Developmental Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York.
Devika GajriaDepartment of Medicine, Center for Developmental Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York.
Richard D CarvajalDepartment of Medicine, Center for Developmental Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York.
Alan L HoDepartment of Medicine, Center for Developmental Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York.
Jan H BeumerCancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Brian KieselCancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Zhigang ZhangDepartment of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Alice ChenCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland.
Richard F LittleCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland.
Christine JarjiesMemorial Sloan Kettering Cancer Center, New York, New York.
Thu O DangMemorial Sloan Kettering Cancer Center, New York, New York.
Fallon FranceMemorial Sloan Kettering Cancer Center, New York, New York.
Nishant MishraMemorial Sloan Kettering Cancer Center, New York, New York.
John F GerecitanoDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · USKettering University · USNational Cancer Institute · MYUniversity of Pittsburgh · USUPMC Hillman Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0MNCI ET-CTN with Phase i Emphasis at UPCIUM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani · 2014 to 2026
$9.1MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA047904NCI NIH HHS UM1 CA186690
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBenzimidazolesDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansLymphoma, B-CellMaleMaximum Tolerated DosePoly(ADP-ribose) Polymerase InhibitorsRituximabBendamustine HydrochlorideBenzimidazolesPoly(ADP-ribose) Polymerase InhibitorsRituximabveliparib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.